view more →
410 Medical is dedicated to developing innovative products that help emergency clinicians provide better care for critically ill patients.
view more →
Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs.
view more →
Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research.
view more →
AN2 is a biopharmaceutical company focused on developing novel medicines. IPO in March 2022 (NASDAQ: ANTX)
view more →
Developer of scientific data management software designed to enhance workplace collaboration and accelerate the rate of drug discovery. Acquired by PerkinElmer (NYS: PKI) in March 2011.
view more →
AtaCor Medical is developing a novel extracardiac pacing system that does not require leads or hardware to be placed inside or onto the heart.
view more →
Providing in-home primary care for seniors with complex conditions, especially those with dementia
view more →
Avivomed engages in developing neuromodulation therapy intended to treat unmet clinical needs.
view more →
Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2.
view more →
Ed-tech platform that pairs high achieving, under-resourced students with mentors to guide them to successful career outcomes
view more →
Their clinical research software accelerates timelines by automating multiple high impact processes.
view more →
Bivarus is a healthcare IT company that has developed an elegant and efficient patient survey platform. Acquired by Press Ganey Associates in January 2018.
view more →
Boomerang Medical is developing a technology to advance the treatment of autoimmune diseases by using electrical nerve stimulation
view more →
(BITT) is a Boston-based biopharmaceutical company developing immune-based approaches for the treatment of cancer and infectious diseases.
view more →
Cardiosense is building a physiological waveform data platform that leverages novel multi-modal sensors and industry-leading AI
view more →
Manufacturer of late-stage clinical biopharmaceutical products. IPO in June, 2016 (NASDAQ:CLSD).
view more →
Clinipace is a clinical research organization whose services are enhanced by a proprietary on-demand software platform and clinical research services. Acquired by dMed in April 2021.
view more →
Developer of an online platform for clinical payments. Acquired by BioClinica on January 19, 2016.
view more →
Contego Medical has developed a platform based on the integration of an embolic protection filter and a treatment device into one single catheter.
view more →
Provider of genomic and biomedical computing platform intended to empower scientists and clinicians. Acquired by Veritas Genetics in August 2017.
view more →
CVRx has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. IPO in June 2021 (NASDAQ: CVRX).
view more →
Developer of a technology designed to extract highly sensitive nucleic acid quantification. Acquired by Bio-Rad 2021
view more →
Provider of a clinical research platform intended to revolutionize the clinical research industry
view more →
Developer of a system to enhance embolic cerebral protection. Acquired by Edwards Lifesciences (NYSE: EW) in March 2011.
view more →
Endogenex is a clinical stage company, founded to improve outcomes for people living with Type 2 Diabetes.
view more →
Developer of biologic and medical device technologies for wound management designed to improve the safety and availability of human blood supply.
view more →
The company’s small-molecule therapies focus on cyclin-dependent kinases and CDKs. IPO in May 2017 (NASDAQ: GTHX).
view more →
GeneCentric Therapeutics is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs.
view more →
Gozio promotes loyalty and growth for a health system by creating a system-specific app that enhances the patient experience.
view more →
Developer of injectable controlled release technologies designed to reduce the frequency of dosing for ocular therapies. IPO in September 2020 (NASDAQ: GRAY).
view more →
Provider of a histotripsy platform designed for the treatment of cancer. Acquired by Bezos Expeditions, Wellington K5 Global 2025
view more →
Huma.ai is a next-generation low code/no code data science solution for the life sciences industry.
view more →
Engages patients and families in a personalized way to initiate discussions on end-of-life care planning. Acquired by Aledade in January 2022.
view more →
iVEAcare is developing innovative neuromodulation therapy to treat unmet clinical needs impacting large patient populations.
view more →
Founded by pediatricians, developing medical content in an educational format embraced by children. Acquired by Falfurrias 2024
view more →
Kymera is developing a heterobifunctional small molecule drug platform. IPO in August 2020 (NASDAQ: KYMR).
view more →
Developer of innovative neurodegeneration small-molecules intended to establish a platform for novel drug discovery.Acquired by Bial in October 2020.
view more →
Provider of patient experience platform designed to facilitate the relationship between physicians and patients. Acquired by NextGen 2019
view more →
We have developed a novel liquid biopsy assay platform which interrogates tumor-derived extracellular vesicles.
view more →
Operator of a biopharmaceutical agency intended to offer drugs for the treatment of diabetes and other metabolic disorders.
view more →
Developer of staffing, communication and schedule management tools designed to modernize staffing processes. Acquired by HealthStream 2020
view more →
The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor. IPO in October, 2018 (NASDAQ:PHAS)
view more →
Perfuse Therapeutics, Inc. is a seed stage biotechnology company focusing on improving retinal perfusion
view more →
Developer of a molecular diagnostics technology designed to dramatically reduce time to results in microbiology.
view more →
A developer of multiple antibiotic drugs intended to combat antimicrobial resistance. Acquired by Shionogi 2023
view more →
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke.
view more →
The SHAPE-MaP technology developed in the lab of Dr. Weeks identifies functional motifs within RNA by mapping the RNA three-dimensional structure.
view more →
Developer of epigenetic drugs intended to be used for the treatment of cognitive disorders and diseases of the brain. Acquired by NASDAQ: ALKS in Nov 2019
view more →
Software and logistics solution for physicians allowing them to become independent DME suppliers
view more →
SafeRide’s technology provides end-to-end data transparency while improving patient experience, population health, and program efficiency.
view more →
Shattuck Labs is a clinical-stage biotechnology company for the treatment of cancer and autoimmune disease. IPO in October 2020 (NASDAQ: STTK)
view more →
Standard Bariatrics is developing a clamp and stapler to standardize sleeve gastrectomy procedures. Acquired by Teleflex in September 2022.
view more →
Stridebio is developing engineered viral vectors for gene therapy. Acquired by Ginkgo Bioworks 2023
view more →
Platform linking natural compounds and ethnobotanical evidence to generate novel drug candidates
view more →
Synaptrix is focused on developing and commercializing drug-free, long-lasting solutions for post-operative pain management.
view more →
Ten63 Therapeutics is focused on improving human health by developing better, more durable therapeutics against cancer and some of the world’s most lethal diseases.
view more →
Developer of novel engineered compounds designed to corneal dystrophies, improve human health and create new therapies using drugs developed with protein engineering.
view more →
The company’s lead drug has potential to be a game-changer in the treatment of HITT. Acquired by Cadrenal Therapeutics 2025
view more →
Developer of therapies based on metalloenzyme chemistry and biology platform. Acquired by NovaQuest Capital Management in January 2018.
view more →
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. IPO in January 2022 (NASDAQ: VIGL).
view more →
Provides analytics and software infrastructure to support the operations of social care networks, Medicaid waiver programs, and value-based care organizations
view more →
Sleep management platform built to address sleep conditions from testing through ongoing care via a wearable patch
view more →
Developer of health engagement platform intended to connect families to health resources on the smartphone.
